/ Print /

PHARMACY BEST PRACTICES

Consumers’ top 4 concerns about their physiciansA Physicians Foundation survey gives healthcare executives behind the scenes insight into the physician-patient relationship.
Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Payers can predict budget implications of high-cost drugs in the pipelineA University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Meeting the ‘status quo’ with CMS Star Ratings equals regressionCMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Payers need access to pre-approval drug informationPre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Survey: How payers use nonpayer generated data to make formulary decisionsExternal, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.